GSA Capital Partners’s Kinnate Biopharma Inc. Common Stock KNTE Stock Holding History

GSA Capital Partners’s Portfolio KNTE Stock Details KNTE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-334,694	Closed	-$890K	–	2133
2024 Q1	$890K	Sell	334,694 -4,292	-1%	-$10.6K	0.07%	519
2023 Q4	$803K	Sell	338,986 -35,305	-9%	-$62.5K	0.07%	509
2023 Q3	$524K	Buy	374,291 +133,948	+56%	+$322K	0.04%	763
2023 Q2	$728K	Buy	240,343 +203,220	+547%	+$783K	0.07%	504
2023 Q1	$232K	Sell	37,123 -33,051	-47%	-$201K	0.02%	1178
2022 Q4	$428K	Sell	70,174 -3,103	-4%	-$25.3K	0.05%	699
2022 Q3	$876K	Buy	73,277 +16,898	+30%	+$221K	0.12%	217
2022 Q2	$711K	Buy	56,379 +9,204	+20%	+$85.7K	0.11%	294
2022 Q1	$531K	Buy	+47,175	New	+$519K	0.07%	484

GSA Capital Partners's KNTE Position: Q2 2024 in Review

GSA Capital Partners sold out of Kinnate Biopharma Inc. Common Stock (KNTE) in Q2 2024, closing a stake of 334,694 shares — an estimated $890K sold.

GSA Capital Partners first reported a position in KNTE in Q1 2022 and held it in 9 quarters. The position peaked at $890K in Q1 2024. 0 funds tracked by Wall St. Rank hold KNTE as of Q2 2024.

GSA Capital Partners reported no remaining Kinnate Biopharma Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
GSA Capital Partners sold 334,694 Kinnate Biopharma Inc. Common Stock shares in Q2 2024, an estimated $890K.
GSA Capital Partners first reported a position in Kinnate Biopharma Inc. Common Stock in Q1 2022 and held it in 9 quarters.
GSA Capital Partners's Kinnate Biopharma Inc. Common Stock position peaked at $890K in Q1 2024.
0 funds tracked by Wall St. Rank held Kinnate Biopharma Inc. Common Stock as of Q2 2024.

Based on GSA Capital Partners's 13F filing for Q2 2024, filed 15 Aug 2024.